BTIG Reiterates Buy Rating on vTv Therapeutics (VTVT): "Street overlooking small molecule portfolio"
Tweet Send to a Friend
BTIG analyst Kambiz Yazdi reiterated a Buy rating and $49.00 price target on vTv Therapeutics (NASDAQ: VTVT)The analyst commented, "vTv ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
